| Literature DB >> 31138979 |
Angela Yuen1, Bailey Crandall1.
Abstract
Patients who have or are at high risk for developing cardiovascular disease and who are taking tyrosine kinase inhibitors for renal cell carcinoma should receive routine cardiovascular event monitoring during the first 4 months of therapy.Entities:
Year: 2019 PMID： 31138979 PMCID： PMC6533895
Source DB: PubMed Journal: Fed Pract ISSN： 1078-4497